<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30290280</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>13</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>13</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1768-3254</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>159</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>European journal of medicinal chemistry</Title>                <ISOAbbreviation>Eur J Med Chem</ISOAbbreviation>            </Journal>            <ArticleTitle>Synthesis, molecular docking and inhibition studies of novel 3-N-aryl substituted-2-heteroarylchromones targeting microtubule affinity regulating kinase 4 inhibitors.</ArticleTitle>            <Pagination>                <MedlinePgn>166-177</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0223-5234(18)30802-X</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2018.09.030</ELocationID>            <Abstract>                <AbstractText>A series of 3-N-aryl substituted-2-heteroarylchromones was efficiently synthesized via Pd-mediated oxidative coupling under the influence of hetero-atoms neighboring group participation. Synthesized molecules were evaluated against human microtubule affinity regulating kinase 4 (MARK4) enzyme inhibitors, a recently identified anti-cancer drug target. Among 21 synthesized molecules, compounds 2, 3, and 14 exhibited excellent in vitro inhibitory effect against MARK4 with IC<sub>50</sub> value (50% of ATPase activity) at 2.12 ± 0.22 μM, 1.98 ± 0.34 μM and 5.56 ± 0.42 μM respectively. The fluorescence binding and dot blot assay of these compounds were found in μM range, indicating a better binding affinity. In vitro study of these compounds against cancerous cells (MCF-7 and HepG2) inhibited the cell viability, induced apoptosis and lowered the tau-phosphorylation. Cell viability studies of compounds 2, 3, and 14 showed inhibition of cancerous cells growth with IC<sub>50</sub> values of 3.22 ± 0.42, 4.32 ± 0.23 μM and 16.22 ± 1.33 μM for human breast cancer cells (MCF-7) and 6.45 ± 1.12, 5.22 ± 0.72 μM and 19.12 ± 1.43 μM for human liver carcinoma cells (HepG2) respectively. ROS quantification of these compounds showed oxidative stress to cancerous cells and molecular docking study showed hydrogen bonding, charge or polar and van der Waals interactions with the active site residues of MARK4. Owning to high binding fit nicely in the active site, offering the possibilities to be used as novel therapeutic molecules in the drug discovery against MARK4-related diseases.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Parveen</LastName>                    <ForeName>Iram</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry, Indian Institute of Technology Roorkee, Roorkee, 247 667, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Khan</LastName>                    <ForeName>Parvez</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, 110025, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ali</LastName>                    <ForeName>Sher</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, 110025, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hassan</LastName>                    <ForeName>Md Imtaiyaz</ForeName>                    <Initials>MI</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, 110025, India.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ahmed</LastName>                    <ForeName>Naseem</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemistry, Indian Institute of Technology Roorkee, Roorkee, 247 667, India. Electronic address: nasemfcy@iitr.ac.in.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>France</Country>            <MedlineTA>Eur J Med Chem</MedlineTA>            <NlmUniqueID>0420510</NlmUniqueID>            <ISSNLinking>0223-5234</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D002867">Chromones</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.1.-</RegistryNumber>                <NameOfSubstance UI="C483047">MARK4 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 2.7.11.1</RegistryNumber>                <NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002867" MajorTopicYN="N">Chromones</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D056945" MajorTopicYN="N">Hep G2 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D062105" MajorTopicYN="Y">Molecular Docking Simulation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017346" MajorTopicYN="N">Protein-Serine-Threonine Kinases</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">3-N-Aryl substituted-2-heteroarylchromones</Keyword>            <Keyword MajorTopicYN="N">Anti-proliferative activity</Keyword>            <Keyword MajorTopicYN="N">Binding affinity</Keyword>            <Keyword MajorTopicYN="N">MARK4 inhibitors</Keyword>            <Keyword MajorTopicYN="N">Transition metal catalyzed C-H amination</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>04</Month>                <Day>22</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>08</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>14</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30290280</ArticleId>            <ArticleId IdType="pii">S0223-5234(18)30802-X</ArticleId>            <ArticleId IdType="doi">10.1016/j.ejmech.2018.09.030</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>